{"schema_version":"secwatch.filing_event.v1","accession":"0002019410-26-000053","form_type":"8-K","ticker":"CAI","cik":"0002019410","company_name":"Caris Life Sciences, Inc.","filed_at":"2026-08-05T20:12:27+00:00","discovered_at":"2026-08-05T20:14:01.275068+00:00","generated_at":"2026-08-05T20:14:45.173591+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Caris Life Sciences Q2 revenue up 45% to $263.7M; raises FY 2026 guidance to $1.03-1.04B","bullets":["Revenue $263.7M (+45% YoY); net loss narrowed to $0.6M from $71.8M loss; positive Adj. EBITDA $55.7M.","Clinical cases ~59,200 (+18% YoY); gross margin improved 500 bps to 68%.","Raised 2026 revenue guidance to $1.03-1.04B (27-28% growth); reaffirmed ~20% clinical therapy selection volume growth.","Launched Caris Detect multi-cancer early detection blood test and Caris ChromoSeq for myeloid malignancies.","Share repurchase program of up to $100M authorized; $82.1M remains available."],"urls":{"canonical":"https://secwatch.observer/filing/0002019410-26-000053","json":"https://secwatch.observer/filing/0002019410-26-000053.json","markdown":"https://secwatch.observer/filing/0002019410-26-000053.md","text":"https://secwatch.observer/filing/0002019410-26-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000053/0002019410-26-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000053/cai-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:14:45.173591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}